Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine Versus a Licensed Comparator in Children

Model scores of the 29,894 trials active now.

Model score 3% for any early termination, 0% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 6% of the time (876 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2009-06-01. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: time ofprotocolthe timebiologicalsin children
  Phrases that lowered it: vaccineinfluenzasafety ofimmunogenicityreceipt
• Accepts healthy volunteers: Yes (lowers risk) · Who can join
• Sponsor's past termination rate: 3.6% (lowers risk) · Sponsor's track record
• Primary purpose: prevention (lowers risk) · Design
• Phase: 3 (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 531 (raises risk) · Sponsor's track record
• Has a data monitoring committee: not given (lowers risk) · Design
• Sponsor's past trials: 823 (raises risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Minimum age: 0.5 (lowers risk) · Who can join
• Maximum age: 2.92 (lowers risk) · Who can join
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Disease area, cancer: No (lowers risk) · Disease area
• Blinding: double (raises risk) · Design
• Number of arms: 3 (lowers risk) · Design
• Drug's FAERS reports marked serious: no FAERS history (raises risk) · Drug's FDA history
• Drug's FAERS reports with a death: no FAERS history (raises risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine (GSK2282512A) Compared to Fluzone® Quadrivalent in Children 6 to 35 Months of Age NCT02242643 · started 2014 · scored riskier than 4% of active trials completed
• Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine GSK2282512A When Administered to Children 6 to 35 Months of Age NCT01711736 · started 2012 · scored riskier than 2% of active trials completed
• Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine GSK2282512A When Administered to Children From 6 to 35 Months of Age NCT01974895 · started 2013 · scored riskier than 3% of active trials completed
• Clinical Study in Children, 6 Months to 3 Years of Age, to Assess Two Dose Levels of an Experimental Flu Vaccine, Using a Licensed Influenza Virus Vaccine, Vaxigrip® as the Control NCT00778895 · started 2008 · scored riskier than 2% of active trials completed
• An Efficacy Study of GlaxoSmithKline (GSK) Biologicals' Candidate Influenza Vaccine GSK2321138A in Children NCT01439360 · started 2011 · scored riskier than 2% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.